Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Future of breast cancer care: HER2 therapies in earlier settings & de-escalation

Sibylle Loibl • 10 Dec 2020
SABCS 2020
Breast Cancer

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses future advances in breast cancer care, including how anti-HER2 therapies will evolve in earlier settings, as well as upcoming data in de-escalation studies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sibylle Loibl

1:28
Long-term survival of the Phase II GeparOLA study
Sibylle Loibl • 6 Dec 2022
0:36
Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer
Sibylle Loibl • 6 Dec 2022
1:43
Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancer
Sibylle Loibl • 6 Dec 2022
1:03
Key takeaways from SABCS 2022
Sibylle Loibl • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals